Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis

Histopathology. 2020 Oct;77(4):548-559. doi: 10.1111/his.14092. Epub 2020 Sep 10.

Abstract

Aims: The peritoneal regression grading score (PRGS) and peritoneal cytology (PC) assess response to chemotherapy in peritoneal metastasis (PM) in a setting of palliative treatment by pressurized intraperitoneal aerosol chemotherapy (PIPAC). Progression has been defined as an increase of PRGS between first and third PIPAC procedures (iPRGS). iPRGSand positive peritoneal cytology were not associated with prognostic impact. These results may be explained by a lack of statistical power. Also, it is not known whether the mean or the highest PRGS among taken peritoneal biopsies bears the highest clinical value. We therefore conducted the largest prospective study to investigate the prognostic impact of PGRS, PC, and their combination, designated as combined progression index (CPI).

Methods and results: Patients with PM who underwent >3 PIPAC (n = 112) between December 2016 and February 2019 were prospectively included. A significant difference in OS and PFS according to CPI (used highest value of PRGS) was found (OS: CPI-, 83.3, 95% CI [49.8; NA] vs. CPI+, 48.1, 95% CI [38.5; 66.4] months; and PFS (respectively, 59.7, 95% CI [43.0; 96.0] vs. 33.7, 95% CI [30.4; 44.2] months). PRGS or PC had no independent prognostic impact. CPI+ was an independent predictor of worse prognosis, in OS (HR = 5.24, 95% CI [2.07; 13.26]), and PFS (HR = 4.41, 95% CI [1.40; 13.88]).

Conclusions: The CPI based on highest PRGS and PC was found to be independently associated with a worse prognosis for OS and for PFS in the setting of peritoneal metastasis. These results indicate that it should be of interest to systematically take peritoneal fluid for cytological examination and to implement the CPI in the therapeutic decision-making process in the context of PIPAC.

Keywords: PIPAC; PRGS; peritoneal cytology; pressurised intraperitoneal aerosol chemotherapy; tumour regression grading.

MeSH terms

  • Adult
  • Aerosols
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage*
  • Biopsy
  • Chemotherapy, Adjuvant / methods
  • Cytodiagnosis / methods*
  • Disease Progression
  • Drug Delivery Systems
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading / methods
  • Neoplasm Metastasis / diagnosis*
  • Neoplasm Metastasis / drug therapy*
  • Peritoneal Neoplasms / diagnosis*
  • Peritoneal Neoplasms / drug therapy*
  • Prognosis
  • Progression-Free Survival
  • Prospective Studies

Substances

  • Aerosols
  • Antineoplastic Agents